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Abstract 
Aims: Clinical trial patients are highly motivated but may encounter difficulty in 
taking study medication regularly when treatment burden is substantial. We 
assessed a brief behavioural intervention, given in addition to a standard trial 
protocol. 
Methods: We performed a two-arm adherence sub-study, within a twelve-month 
randomised controlled drug trial evaluating the impact of statin and/or omega-3 EE90 
treatment in 800 patients with type 2 diabetes, in 59 United Kingdom general 
practices cluster-randomised to action-planning or control groups. The former 
delivered an initial written exercise prompting participants to formulate action-plans 
to take study medication regularly, with brief nurse encouragement to use action-
plans at later visits, whilst the latter followed the standard trial protocol. The primary 
outcome was proportion of days on which study medication were taken as intended 
measured by electronic medication containers. 
Results: Adjusted mean (95% CI) proportion of days with medication taken as 
intended was 79.3% (76.3% to 82.3%) for the 30 action-planning practices (321 
participants), compared with 78.5% (75.8% to 81.1%) for the 29 control group 
practices (479 participants, with a mean intervention effect of 0.9% (95%CI -3.1% to 
+4.9%, p=0.67). Adjusted odds ratios for ≥80% trial medication adherence for action-
planning compared with control practices were 1.29 (0.90 to 1.84) and 1.38 (0.96 to 
1.99) respectively.  
Conclusions:  Low-intensity action-planning interventions used alone are unlikely to 
have a clinically important impact on medication adherence. These findings, do not 
exclude their contribution, as part of a multifactorial intervention, to improving 
treatment adherence. ISRCTN number 76737502. 
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• Clinical trial participants are highly motivated to take study medication, but 
may have problems in doing so if the medication burden is high. 
• Action plans are a promising approach for people who forget to take their 
medicines.  
• There have been no large-scale evaluations of this approach. 
• We did a large, cluster-randomised trial to evaluate the impact of an action 
planning based intervention on study medication adherence compared with a 
standard trial protocol. 
• We exclude a clinically important effect of action-planning intervention alone, 





Diabetes is a major public health problem. The prevalence is projected to reach 642 
million by 2040,[1] with a high clinical and economic burden as people with diabetes 
have a two-to four fold increased risk for cardiovascular disease compared to the 
general population, and an increased incidence of retinopathy, peripheral nerve 
damage and renal problems.[2] Treatment with statins (HMG-CoA reductase 
inhibitors) reduces the risk of a first cardiovascular event in people with diabetes, 
even in those without high baseline LDL cholesterol values.[3] However, up to half of 
medication for diabetes may not be taken as prescribed, including statin therapy. 
Medication non-adherence reduces treatment efficacy and wastes healthcare 
resources.  
Interventions to promote adherence need to be sufficiently effective to justify 
their cost, with the components straightforward to deliver, particularly when 
implemented at scale. Non-adherence falls into two broad categories: (i) that arising 
from the patient’s decision to take less medication than prescribed or to miss a dose 
or day of medication (intentional non-adherence); (ii) forgetting to take medication 
(non-intentional non-adherence).[4] One approach for people who forget to take 
medicines is to help them define specific action plans that will increase the chances 
of carrying out the desired behaviour and establishing a regular habit.[5] Previous 
work using this approach includes increasing consumption of vitamin C pills,[5] 
attendance for cervical cytology screening [6] and uptake of breast self-
examination.[7]  
 Clinical trial participants are often highly motivated to take the study 
medication, but may still encounter difficulty in taking it regularly. This is particularly 
so when there is a high burden of medication and when the trial period extends 
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beyond a few weeks. The Atorvastatin in Factorial with Omega fatty acids for Risk 
Reduction in type 2 Diabetes (AFORRD) trial, a one-year, primary care based 
factorial design clinical trial investigating the impact of statin and/or omega-3 EE90 
treatment on estimated cardiovascular risk with statins provided an opportunity to 
test the effectiveness of an embedded action-planning intervention. 
This sub-study aimed to assess the degree to which an action planning 
intervention could improve adherence to trial medication when added to the standard 
trial procedures.[8]  
Methods 
 Study setting and population 
We performed a cluster-randomised sub-study, embedded within the AFORRD trial 
run by the University of Oxford Diabetes Trials Unit in an academic collaboration with 
Pfizer Ltd, in 59 United Kingdom general practices. The protocol was approved by 
local and national ethics committees and carried out in accordance with the 
Declaration of Helsinki and good clinical practice guidelines. The study design, 
inclusion criteria, and primary results have been published.[8] AFORRD participants 
were recruited between November 2004 and July 2005. 
Randomisation 
Following recruitment of their first AFORRD participant, participating practices were 
matched in pairs for size and location and randomly allocated by a statistician with 
no involvement in the sub-study to receive either the additional action-planning 
intervention (action-planning group) or the standard trial protocol (control group).  
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Intervention 
Action-planning group participants were asked to complete an extra task when 
completing other self-reported trial measures in a questionnaire sent by post two 
weeks after the first medication-dispensing visit. This task was a written exercise, 
presented on a single sheet of paper as two additional questions, asking the 
participant to formulate a written plan for taking their study medication. The two 
questions (“When do you plan to take your study medication?” and “Where do you 
plan to take your study medication?”) were intended to help the participant specify a 
series of contingent circumstances that would help prompt them to take their 
medication, e.g. “When I brush my teeth in the morning in the bathroom, I will take 
my trial medicines”. At the two subsequent general practice visits (18 and 32 weeks) 
these action-planning sheets were again completed by trial participants attending 
practices allocated to deliver the action planning intervention. At these two visits, the 
practice based research nurse also asked whether participants had concerns about 
the medication and encouraged the participants to complete action-planning sheets 
at 18 and 32 weeks by giving information about the benefits of making action plans 
for taking medication as prescribed. These discussions were intended to be brief, 
e.g. to last no more than one minute.  
  Control group practice participants were asked to complete the self-reported 
trial measures as specified in the study protocol at the same time points as action 
planning group participants completed their action planning sheets. Research nurses 
in the control group practices were asked to check whether participants had 
concerns about taking the study medicines, but were not trained in the use of action-
planning or prompting participants to use action plans to take their medication.  
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 Research nurses in practices allocated to the action-planning and control 
groups received separate documentation and training to ensure fidelity to the sub-
study procedures. Intervention scripts were piloted before the trial. Trial operational 
manuals had sections that were customised and included prompts for the 
intervention, and one hour of training on sub-study procedures was delivered to the 
practice-based research nurses with group-specific training videos. The control 
group video focussed on demonstrating standard trial procedures including advising 
about side-effects of medication. The action planning video demonstrated, in 
addition, the principle of the action-planning intervention so that the nurses could 
practice it themselves and then guide trial participants in completing further action-
planning sheets at their 18 and 32 week visits after the medication dispensing visit. 
The study research nurse followed up practice nurses by telephone.  
 
Procedures 
Two weeks after initial assessment and consent procedures for the main trial and 
sub-study, participants returned to the practice and were given a 16-week supply of 
both trial medications, dispensed in an electronic medication-monitoring device 
(eMems V®, Aardex, Switzerland). AFORRD trial participants were allocated in a 
two-by-two factorial design to a tablet (atorvastatin 20 mg or matched placebo) and 
to a capsule (omega-3 EE90 2g or a matched placebo). Practice research nurses 
were trained to show trial participants how to use the eMems device, which 
maintained a record of the clock time and date whenever the container cap was 
removed. Two weeks after the first medication-dispensing visit, all participants 
received a two-page self-report questionnaire about perceived risks of future heart 
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disease, with a medication action-planning sheet for those in the action-planning 
group. 
 At 16 weeks, participants attended a brief assessment visit at which they 
received a further two-week supply of study medication. They were seen again at 18 
weeks and given a further 14 weeks study medication supply. This included an 
additional tablet (atorvastatin or placebo) to intensify lipid-lowering therapy in those 
with an estimated 10-year cardiovascular risk ≥20%. Action-plan practice participants 
completed a further action-planning sheet, with additional explanation if needed from 
the nurse. At 32-weeks, study medication was provided for the final 20-week study 
period and participants in action-planning group practices completed a further action-
planning sheet.  
 Additional measurements were collected at the 52-week final follow-up visit 
and the eMems devices for each of the three study medications (statin, omega-3 
EE90, statin intensification) returned to the coordinating centre for the data to be 
downloaded.  
Outcomes 
The primary outcome for this sub-study was the proportion of days on which all three 
study medications were taken as intended. Secondary outcomes were the proportion 
of study medications taken in each of the four study periods (0-16, 16 to 18, 18-32 
and 32-52 weeks) overall, and for each of the three trial treatments separately. 
eMems devices were read and data uploaded to the clinical database masked to 
group allocation.  
 The trial was intended to allow identification of a difference in study 
medication adherence of five percent between action planning and control groups in 
the proportion of days in which medication was taken as required by the AFORRD 
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trial protocol. We calculated a target sample size of 1000 participants in 70 general 
practices based on a standard deviation of 17 for the number of days on which 
medication is taken per 100 days, alpha 0.05, beta 0.8, interclass correlation 
coefficient (ICC) of 0.05 and 11% inflation to account for drop out following 
randomisation. 
Statistical analysis 
We included data for the primary analysis from all randomised participants, excluding 
those withdrawn because of site-specific protocol violations where the wrong 
questionnaire was handed out to participants at two sites.  
 Data are presented as means  (1 SD), with estimated intra-cluster correlation 
coefficients (95% confidence intervals).  The primary study analysis of overall 
adherence used a significance level of 5%. Other pre-specified analyses included 
the measures of adherence for each of the three trial treatments and changes in 
adherence over the course of the trial. A predefined subgroup analysis was carried 
out to test for interaction between participant characteristics and adherence.  
 Two measures of medication adherence were derived from the electronic 
monitoring data: (i) the primary outcome - mean percentage of days on which the 
correct dose of medication was taken; (ii) the proportion of participants taking ≥80% 
of their medication. Mean measures of adherence were compared between 
participants registered to practices allocated to the action-planning and control 
groups.  
 Medication was considered taken ‘as prescribed’ if there was one recorded 
opening of the eMems device on a given day. We defined a day as starting at 03.00 
am and ending at 03.00 am the following day.[9] Summary measures of individual 
adherence were calculated as the number of days in which medication was taken as 
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prescribed, divided by the total number of days observed. We calculated mean 
adherence in the action-planning and control groups overall and for each of the four 
study time periods.  
 Generalised estimating equation linear models were used to account for 
clustering within practice and to present mean adherence (95% confidence intervals) 
based on robust standard errors.  Summary measures were derived using R (R -
Foundation, Vienna, Austria) and models fitted using Stata version 11.2. 
 Between group trends for the proportion of participants taking medication on 
each day were examined by fitting regression lines for the action-planning and 
control groups over the whole trial, assuming that an intercept not different to zero 
would indicate no difference in treatment adherence.  
 Neither the sponsor nor the funder had any role in trial design, interpretation 
or reporting of the trial.  
Results 
A participant flow diagram is shown in Figure 1. 800 participants were recruited in 59 
practices, 30 computer-allocated at random to action-planning (321 participants), 
and 29 (479 participants) to the control group. A total of 53 patients registered with 
two control group practices were excluded from the analysis as they were found to 
have incorrectly received action-planning intervention self-report measures during 
the study. In total 321 participants in 30 practices received the additional action-
planning intervention and 426 participants in 27 practices received the standard trial 
protocol. 
  Baseline participant characteristics are shown in Table 1. The action-planning 
group were slightly younger than the control group, and had fewer male participants. 
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Table 2 shows the impact of the action-planning intervention compared with control, 
with no difference between groups in the primary outcome for all medication streams 
over one year, with a between group difference of 0.9% (-3.1% to +4.9%). There was 
a small, non-significant but consistent higher adherence in the action-planning group 
over the course of the study of between 2% and 4% after adjustment for the intra-
cluster effects, most apparent between the start of the trial and 32 weeks across 
each of the reported outcomes for adherence to individual medications and their 
combinations.  
 Figure 2 provides a descriptive analysis of persistence with study medication 
at the group level in the extent to which the tablet and capsule streams were taken 
over the course of the study. Trends for the proportion of participants taking 
medication on each day of the trial between groups were significantly different (p < 
0.001). The estimate (95% confidence intervals) of difference over-time was 1.9% 
(1.3% to 2.4%), corresponding to the estimates of mean differences in adherence 
derived from individual data. 
 Secondary analyses of the proportion of participants taking ≥80% of each 
medication stream over the full treatment period gave an adjusted odds ratio of 1.29 
(0.90 to 1.84, p=0.16) for statin tablets and 1.38 (0.96 to 1.99, p=0.08) for omega-3 
EE90 capsules, with 1.24 (0.81 to 1.89, p=0.32) for the statin intensification tablets. 
Pre-planned sub-group analyses showed no interactions between adherence and 




Although this trial provides no evidence for a clinically-relevant action-planning 
intervention impact, it does not exclude a small effect of such an approach on the 
extent to which people take their trial medication. The results suggest a consistent, 
trend with an estimated 2% and 3% increase in the proportion of study medication 
taken when comparing the action-planning with the control group.  Additional 
analyses provide a consistent picture, with a significant difference in the proportion of 
participants taking >80% of their trial capsule medicines, and an overall analysis of 
the proportion of participants taking their initial statin tablet as the trial progresses 
showing a significant difference in trends as this proportion falls over time. This is a 
population likely to be more adherent to medication having been self-selected for 
participation in a clinical trial. Not withstanding the characteristics of the trial 
participants, this study raises the possibility of a small effect on adherence. 
Strengths and limitations  
This was a challenging intervention to implement within the framework of a 
randomised controlled trial where motivation to take study medication was likely to 
be high. Despite this, the average proportion of study medication taken was around 
80% of that intended. Procedures were designed to be practical and consistent, with 
use of a standardised action-planning sheet to help ensure uniform intervention 
delivery, and the use of videos sent to practice nurses after participants had been 
recruited to provide training. However, objective evidence that this training translated 
into fidelity to use of the intervention by participants is not available. Electronic 
medication monitors were used to provide an objective measurement of adherence, 
which had additional advantages in carrying out subsequent exploratory analyses to 
establish response to medication.[10]  
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 There were a number of practical difficulties encountered in embedding the 
cluster study within a randomised trial. For example, the total number of participants 
recruited (and determined by recruitment to the main AFORRD trial) was less than 
originally envisaged, so the trial did not have the planned power to identify 
differences of the size observed. Although electronic medication monitoring has the 
potential to affect adherence, other studies have not demonstrated that it has a 
clinically significant impact.[11] In addition, differing rates of recruitment to each 
practice after randomisation and in the eighteen weeks after recruitment of the first 
participant in each practice, led to an unintended unbalanced allocation of 
participants. As with any cluster-randomised study, it is not possible to fully exclude 
systematic differences between populations. However, the initial similarities in 
adherence observed over the first two weeks of the study before implementation of 
the intervention would suggest that groups were similar in their adherence 
behaviour. 
Relationship to previous studies 
This study was carried out in a population similar to those of motivated individuals 
receiving care for type 2 diabetes where adherence rates of 80% to 90% have been 
observed. [12] Previous intervention studies have often used imprecise 
measurement of adherence. Systematic reviews show mixed results to a wide range 
of interventions, targeted at both patients and health systems, to support 
adherence.[13] Multi-component and intensive interventions appear to be more 
effective, but the extent to which the success of interventions is dependent on 
specific characteristics of the setting is often unclear.  
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Interpretation and significance 
Summary statistics that are estimated over an aggregate period of time provide only 
a limited account of trends in the implementation of the dosing regimen over 
time.[14] The effects of the action planning intervention on adherence noted here 
might not be sufficient to lead to changes in drug levels that would affect lipid levels 
achieved. Statins, for example, have a long duration of effect. However, interventions 
in this population that improve adherence are likely to be possible, but will be multi-
component, utilising a number of strategies, including addressing motivation, 
providing feedback on medication use and supporting medication taking as a 
habitual behaviour.  Action planning is a low-cost intervention that could be delivered 
at scale and thus might form a component of innovative approaches to supporting 
medication adherence. Modelling to establish the conditions under which these small 
effects on adherence might lead to a cost-effective intervention before carrying out 
further research would be helpful.  
Conclusion 
Interventions using low-intensity action-planning only are unlikely to have a clinically 
important impact on medication adherence. However, these findings do not exclude 
the possibility that self-completed action plans, supported by brief advice from 
clinical staff, could improve adherence to treatment as a component of a 
multifactorial intervention, particularly if delivered at scale and low cost. 
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Figure 2. Proportion of trial participants in the action-planning and control groups 




 Footnote for Figure 2. Difference in adherence between the active and control 




Table 1. Baseline participant characteristics by randomised allocation 
 
 Action-planning Standard practice   
Number of practices 30 29 
Number of participants 321  479 
Gender (male)1  174 (54%)  285 (59%) 0.14 
Age (years)2  61.5 (11.1)  63.9 (12.0)  0.004 
Ethnicity1 
White  308 (96.0%)  415 (86.6%)  
Asian/Asian British  8 (2.5%)  31 (6.5%) 
Black/Black British  4 (1.2%)  29 (6.1%) 
Other  1 (0.3%)  4 (0.8%) 0.001 
Diabetes duration (years)3  4.7 (1, 7)  5.1 (1, 7)  0.28 
Weight (kg) 2  89.4 (19.9)  86.8 (18.9)  0.07 
HbA1c (mmol/mol) 2 52.1 (11.6) 52.4(11.7) 0.75 
HbA1c (%) 2 6.9 (1.1) 6.9 (11.1) 0.75 
Total cholesterol (mmol/l)2  5.1 (0.8)  4.9 (0.9)  0.005 
Self-reported adherence3 24 (23 to 25)  24 (23, 25)  0.86 
 
Data are N (%)1, mean (SD)2, median (Q1, Q2)3 
P values are taken from chi-squared or Kruskal Wallace 
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Table 2. Proportion of days of medication taken (95% confidence interval) for each trial treatment by four study visit periods, 








Table 3. Proportion of days covered (week 2-52) for all medication (or tablets and capsules separately) for pre-defined subgroups 
of the trial population adjusted for cluster effect. 
 
 
  n Intervention Control Diff (Int-Cont) 
p value for 
interaction 
       
Gender 
Male 384 79.7 (75.9 to 83.5) 74.2 (70.4 to 77.9) 3.0 (-1.9 to 8.0) 
0.98 
Female 302 78.0 (73.1 to 82.9) 75.5 (70.9 to 80.0) 2.5 (-4.2 to 9.2) 
       
Age 
<= 63 341 78.8 (74.5 to 83.2) 75.6 (71.5 to 79.8) 3.2 (-2.8 to 9.2) 
0.66 
> 63 345 78.0 (73.3 to 81.0) 77.0 (73.1 to 81.0) 1.0 (-5.1 to 7.1) 
       
HbA1c 
<= 7 % 422 78.9 (75.0 to 82.8) 76.1 (72.8 to 79.4) 1.1 (-4.2  to 6.1) 
0.29 
> 7 % 264 78.4 (73.3 to 83.5) 73.1 (68.1 to 78.1) 5.3 (-1.8 to 12.4) 
       
Duration <= 3 years 393 80.3 (76.5 to 84.1) 76.4 (71.1 to 81.7) 2.9 (-2.2 to 8.1) 
0.81 
 > 3 years 293 76.4 (71.1 to 81.7) 74.6 (70.1 to 79.2) 1.8 (-5.2 to 8.7) 
       
BMI 
<= 30 347 78.8 (74.8 to 82.8) 75.4 (70.8 to 80.1) 2.0 (-3.2 to 7.1) 
0.55 
> 30 339 78.8 (74.1 to 83.4) 74.7 (70.3 to 79.1) 4.1 (-2.4 to 10.6) 
       
Education 
No qualification 361 76.7 (72.1 to 81.4) 77.7 (73.4 to 81.8) -0.9 (-7.2 to 5.3) 
0.28 
Any qualification 325 80.3 (75.4 to 85.1) 74.9 (70.4 to 79.5) 5.3 (-1.3 to 11.9) 
 
